Liping Liu, HighTide Therapeutics CEO

High­T­ide Ther­a­peu­tics rides NASH R&D wave with a $107M raise

High­T­ide Ther­a­peu­tics has raised a $107 mil­lion Se­ries C round to fund mid-stage stud­ies in meta­bol­ic and di­ges­tive dis­eases, with the goal of fil­ing for ap­proval in Chi­na with­in two to three years.

High­T­ide, which has roots in Shen­zhen, Chi­na, and Mary­land, dis­closed the round Thurs­day morn­ing in ad­vance of the JP­Mor­gan health­care meet­ing. CEO and founder Lip­ing Liu told End­points News the fi­nanc­ing would like­ly bankroll the com­pa­ny in­to the 2024 to 2025 time­frame.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.